Article in Glia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 2 institutions in 1 country.
Vanessa L HullDepartment of Neurology, University of California Davis School of Medicine, Sacramento, California, USA.ORCID 0000-0003-3221-740X
Yan WangDepartment of Neurology, University of California Davis School of Medicine, Sacramento, California, USA.ORCID 0000-0002-7744-4078
Travis BurnsDepartment of Neurology, University of California Davis School of Medicine, Sacramento, California, USA.
Sarah SternbachDepartment of Biological Sciences, Kent State University, Kent, Ohio, USA.ORCID 0000-0002-5761-9512
Shuaishuai GongDepartment of Neurology, University of California Davis School of Medicine, Sacramento, California, USA.
Jennifer McDonoughDepartment of Biological Sciences, Kent State University, Kent, Ohio, USA.ORCID 0000-0001-9809-2289
Fuzheng GuoDepartment of Neurology, University of California Davis School of Medicine, Sacramento, California, USA.ORCID 0000-0003-3410-8389
Laura N BorodinskyInstitute for Pediatric Regenerative Medicine, Shriners Hospital for Children, Sacramento, California, USA.ORCID 0000-0003-2937-7023
David PleasureDepartment of Neurology, University of California Davis School of Medicine, Sacramento, California, USA.ORCID 0000-0002-9122-1268
Shriners Hospitals for Children - Erie · USKent State University · US
Funding
UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
UC Davis CTSC TL1 Administrative Supplement to Recognize Excellence in Diversity, Equity, Inclusion, and Accessibility MentorshipTL1TR001861 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MEDICI, VALENTINA · 2016 to 2025
$4.7M
Mechanisms of folate action during nervous system developmentR01NS105886 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Laura Noemi Borodinsky · 2019 to 2026
$2.5M
The curious case of PARP1 in CNS myelin formation and repairR01NS123165 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Fuzheng Guo · 2022 to 2026
$2.5M
Glial HIFa: mechanisms and implications in hypoxia/ischemia-induced oligodendroglial pathologyR01NS123080 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GUO, FUZHENG · 2021 to 2025
$2.3M
Mechanisms of neural activity during neural tube formationR01NS113859 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BORODINSKY, LAURA NOEMI · 2020 to 2024
$2.1M
Using genetic approaches to explore the role of group I PAKs in developmental myelination of the mammalian CNSR21NS125464 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GUO, FUZHENG · 2022 to 2022
$439k
Manipulating N-acetyl-L-aspartate to reverse Canavan leukodystrophyR21NS117386 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PLEASURE, DAVID E. · 2020 to 2020
$432k
Manipulating N-acetyl-L-aspartate transport to treat Canavan leukodystrophyR21NS126173 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PLEASURE, DAVID E. · 2022 to 2023
Canavan disease (CD) is a recessively inherited pediatric leukodystrophy resulting from inactivating mutations to the oligodendroglial enzyme aspartoacylase (ASPA). ASPA is responsible for hydrolyzing the amino acid derivative N-acetyl-L-aspartate (NAA), and without it, brain NAA concentrations increase by 50% or more. Infants and children with CD present with progressive cognitive and motor delays, cytotoxic edema, astroglial vacuolation, and prominent spongiform brain degeneration. ASPA-deficient CD mice (Aspa
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice. · full record | OpenQuestion